Biotech

10/31/22

Alnylam is doing what the IRA is telling it to do

Biotech

Finance

Policy

09/21/22

Saving money for Medicare by abandoning new drugs for Medicare patients

Biotech

Finance

Policy

09/16/22

COVID-19: When RA Capital’s ​“secret” maps go public

Biotech

Culture

08/26/22

Navigating a storm that threatens American biotechnology

Biotech

Policy

08/11/22

The NIH, R&D, and the first mile of the marathon — a conversation with John LaMattina

Biotech

Policy

08/03/22

When life-saving medication should be in aisle three

Biotech

Policy

07/28/22

Innovation and biopharma M&A: feature, not bug

Biotech

Policy

07/13/22

Post-launch, pre-cliff: The R&D Congress ignores

Policy

Biotech

07/08/22

Biotech leaders urge fixes to bad Senate drug deal

Biotech

Policy

06/23/22

How to kill the conversation that makes innovation possible

Biotech

Policy

06/16/22

Right to Try 2.0 doubles down on a bad idea

Biotech

Policy

06/10/22

72 hours to kill: Why can’t we diagnose bacterial infections faster?

Biotech

Science

05/27/22

Biotech’s Dulcius Ex Asperis: The Way Through This Downturn

Biotech

Finance

04/20/22

Nektar’s IL‑2 legacy: The two sides of failure

Biotech

Science

04/19/22

Announcing Sionna: When it comes to Cystic Fibrosis, ​“good enough” isn’t good enough

Biotech

Science

04/08/22

Do stocks trading near cash offer free upside?

Biotech

Finance

04/06/22

Matchmaking for proteins: Introducing TRIANA Biomedicines

Biotech

Finance

03/31/22

“Love notes”: Building trust between board meetings

Biotech

Culture

02/17/22

Movie night with RA Capital’s scientific cartographers

Biotech

Culture

02/03/22

Muckrakers, a righteous senator, and a gene therapy walk into a bar

Biotech

Culture

Policy